辰光医疗
(920300)
| 流通市值：10.72亿 | | | 总市值：13.83亿 |
| 流通股本：6653.17万 | | | 总股本：8584.71万 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 67,742,641.82 | 47,352,708.32 | 25,074,439.29 | 119,001,736.41 |
| 营业收入 | 67,742,641.82 | 47,352,708.32 | 25,074,439.29 | 119,001,736.41 |
| 二、营业总成本 | 96,144,924.52 | 67,813,883.45 | 36,275,290.39 | 165,878,663.16 |
| 营业成本 | 34,055,730.93 | 25,506,756.35 | 17,341,913.99 | 73,493,170.2 |
| 税金及附加 | 1,256,593.65 | 866,136.87 | 348,684.37 | 1,444,836.07 |
| 销售费用 | 17,999,124.51 | 12,268,461.84 | 5,468,888.85 | 29,630,249.91 |
| 管理费用 | 15,992,189.01 | 11,094,975.08 | 4,753,213.89 | 26,939,160.58 |
| 研发费用 | 22,986,402.65 | 15,485,867.51 | 7,231,154.86 | 29,438,979.69 |
| 财务费用 | 3,854,883.77 | 2,591,685.8 | 1,131,434.43 | 4,932,266.71 |
| 其中:利息费用 | 3,751,370.82 | 2,608,486.87 | 1,242,948.18 | 5,198,018.51 |
| 其中:利息收入 | 23,989.39 | 19,730.54 | 12,489.41 | 236,618.66 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 239,046.87 | 126,820.84 | 19,239.45 | 695,523.34 |
| 资产处置收益 | - | - | - | -72,912.53 |
| 资产减值损失(新) | -1,394,339.31 | -1,394,339.31 | 827,510.68 | -22,098,174.01 |
| 信用减值损失(新) | 1,733,594.67 | 1,607,880.96 | 1,105,592.94 | -5,712,971.83 |
| 其他收益 | 2,369,747.76 | 1,532,002.33 | 841,982.45 | 5,315,518.08 |
| 四、营业利润 | -25,454,232.71 | -18,588,810.31 | -8,406,525.58 | -68,749,943.7 |
| 加:营业外收入 | 53,006.94 | 53,598.66 | 52,969.8 | 143,439.06 |
| 减:营业外支出 | 23,142.11 | 19,162 | 19,000 | 57,470.3 |
| 五、利润总额 | -25,424,367.88 | -18,554,373.65 | -8,372,555.78 | -68,663,974.94 |
| 减:所得税费用 | -6,093,699.53 | -3,736,702.87 | 210,146 | -7,765,339.44 |
| 六、净利润 | -19,330,668.35 | -14,817,670.78 | -8,582,701.78 | -60,898,635.5 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -19,330,668.35 | -14,817,670.78 | -8,582,701.78 | -60,898,635.5 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -19,330,668.35 | -14,817,670.78 | -8,582,701.78 | -60,898,635.5 |
| 扣除非经常损益后的净利润 | -21,489,027.34 | -16,207,813.33 | -9,300,549.88 | -68,386,717.22 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.23 | -0.17 | -0.1 | -0.71 |
| (二)稀释每股收益 | -0.23 | -0.17 | -0.1 | -0.71 |
| 九、综合收益总额 | -19,330,668.35 | -14,817,670.78 | -8,582,701.78 | -60,898,635.5 |
| 归属于母公司股东的综合收益总额 | -19,330,668.35 | - | -8,582,701.78 | -60,898,635.5 |
| 公告日期 | 2025-10-30 | 2025-08-28 | 2025-04-29 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |